000168283 001__ 168283
000168283 005__ 20240229133602.0
000168283 0247_ $$2doi$$a10.3390/cancers13071508
000168283 0247_ $$2pmid$$apmid:33805971
000168283 037__ $$aDKFZ-2021-00794
000168283 041__ $$aEnglish
000168283 082__ $$a610
000168283 1001_ $$aKoerber, Stefan A$$b0
000168283 245__ $$aPredicting the Risk of Metastases by PSMA-PET/CT-Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma.
000168283 260__ $$aBasel$$bMDPI$$c2021
000168283 3367_ $$2DRIVER$$aarticle
000168283 3367_ $$2DataCite$$aOutput Types/Journal article
000168283 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1618491706_29767
000168283 3367_ $$2BibTeX$$aARTICLE
000168283 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168283 3367_ $$00$$2EndNote$$aJournal Article
000168283 500__ $$a#LA:E060#
000168283 520__ $$aMen diagnosed with aggressive prostate cancer are at high risk of local relapse or systemic progression after definitive treatment. Treatment intensification is highly needed for that patient cohort; however, no relevant stratification tool has been implemented into the clinical work routine so far. Therefore, the aim of the current study was to analyze the role of initial PSMA-PET/CT as a prediction tool for metastases. In total, 335 men with biopsy-proven prostate carcinoma and PSMA-PET/CT for primary staging were enrolled in the present, retrospective study. The number and site of metastases were analyzed and correlated with the maximum standardized uptake value (SUVmax) of the intraprostatic, malignant lesion. Receiver operating characteristic (ROC) curves were used to determine sensitivity and specificity and a model was created using multiple logistic regression. PSMA-PET/CT detected 171 metastases with PSMA-uptake in 82 patients. A statistically significant higher SUVmax was found for men with metastatic disease than for the cohort without distant metastases (median 16.1 vs. 11.2; p < 0.001). The area under the curve (AUC) in regard to predicting the presence of any metastases was 0.65. Choosing a cut-off value of 11.9 for SUVmax, a sensitivity and specificity (factor 1:1) of 76.0% and 58.4% was obtained. The current study confirms, that initial PSMA-PET/CT is able to detect a relatively high number of treatment-naïve men with metastatic prostate carcinoma. Intraprostatic SUVmax seems to be a promising parameter for the prediction of distant disease and could be used for treatment stratification-aspects which should be verified within prospective trials.
000168283 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000168283 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000168283 650_7 $$2Other$$aPET
000168283 650_7 $$2Other$$aPSMA
000168283 650_7 $$2Other$$aintraprostatic SUV
000168283 650_7 $$2Other$$ametastases
000168283 650_7 $$2Other$$aprostate cancer
000168283 7001_ $$aBoesch, Johannes$$b1
000168283 7001_ $$0P:(DE-HGF)0$$aKratochwil, Clemens$$b2
000168283 7001_ $$aSchlampp, Ingmar$$b3
000168283 7001_ $$aRistau, Jonas$$b4
000168283 7001_ $$aWinter, Erik$$b5
000168283 7001_ $$aZschaebitz, Stefanie$$b6
000168283 7001_ $$aHofer, Luisa$$b7
000168283 7001_ $$aHerfarth, Klaus$$b8
000168283 7001_ $$0P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aKopka, Klaus$$b9$$udkfz
000168283 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b10$$udkfz
000168283 7001_ $$aJaeger, Dirk$$b11
000168283 7001_ $$aHohenfellner, Markus$$b12
000168283 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b13$$udkfz
000168283 7001_ $$00000-0002-6411-4811$$aDebus, Juergen$$b14
000168283 7001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b15$$eLast author$$udkfz
000168283 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers13071508$$gVol. 13, no. 7, p. 1508 -$$n7$$p1508$$tCancers$$v13$$x2072-6694$$y2021
000168283 909CO $$ooai:inrepo02.dkfz.de:168283$$pVDB
000168283 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000168283 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9793347ba83f527b81a22ab75af9378a$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000168283 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000168283 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000168283 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-6411-4811$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000168283 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000168283 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000168283 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000168283 9141_ $$y2021
000168283 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2018$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-11
000168283 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2018$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-11
000168283 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-11
000168283 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000168283 9201_ $$0I:(DE-He78)DD01-20160331$$kDD01$$lDKTK DD zentral$$x1
000168283 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x2
000168283 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000168283 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x4
000168283 980__ $$ajournal
000168283 980__ $$aVDB
000168283 980__ $$aI:(DE-He78)E060-20160331
000168283 980__ $$aI:(DE-He78)DD01-20160331
000168283 980__ $$aI:(DE-He78)C060-20160331
000168283 980__ $$aI:(DE-He78)HD01-20160331
000168283 980__ $$aI:(DE-He78)E050-20160331
000168283 980__ $$aUNRESTRICTED